{"id":"https://openalex.org/W1964513792","doi":"https://doi.org/10.1007/s10637-014-0142-1","title":"A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer","display_name":"A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer","publication_year":2014,"publication_date":"2014-09-23","ids":{"openalex":"https://openalex.org/W1964513792","doi":"https://doi.org/10.1007/s10637-014-0142-1","mag":"1964513792","pmid":"https://pubmed.ncbi.nlm.nih.gov/25248752"},"language":"en","primary_location":{"id":"doi:10.1007/s10637-014-0142-1","doi":"https://doi.org/10.1007/s10637-014-0142-1","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s10637-014-0142-1","pdf_url":null,"source":{"id":"https://openalex.org/S6037287","display_name":"Investigational New Drugs","issn_l":"0167-6997","issn":["0167-6997","1573-0646"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Investigational New Drugs","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5030078141","display_name":"Jaafar Bennouna","orcid":"https://orcid.org/0000-0002-5034-1108","observed_orcids":["https://orcid.org/0000-0002-5034-1108"]},"institutions":[{"id":"https://openalex.org/I4210106090","display_name":"Institut de Canc\u00e9rologie de l'Ouest","ror":"https://ror.org/01m6as704","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210106090"]},{"id":"https://openalex.org/I97188460","display_name":"Nantes Universit\u00e9","ror":"https://ror.org/03gnr7b55","country_code":"FR","type":"education","lineage":["https://openalex.org/I97188460"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Jaafar Bennouna","raw_affiliation_strings":["Institut de Canc\u00e9rologie de l'Ouest, Nantes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut de Canc\u00e9rologie de l'Ouest, Nantes, France","institution_ids":["https://openalex.org/I4210106090","https://openalex.org/I97188460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021695281","display_name":"Marion Deslandres","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210098740","display_name":"Institut universitaire du cancer de Toulouse Oncopole","ror":"https://ror.org/014hxhm89","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017","https://openalex.org/I4210098740","https://openalex.org/I4210128666"]},{"id":"https://openalex.org/I4210128666","display_name":"Institut Claudius Regaud","ror":"https://ror.org/03pa87f90","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210128666"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Marion Deslandres","raw_affiliation_strings":["Medical Oncology Department, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France","institution_ids":["https://openalex.org/I4210098740","https://openalex.org/I4210128666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050098537","display_name":"H\u00e9l\u00e8ne Senellart","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210106090","display_name":"Institut de Canc\u00e9rologie de l'Ouest","ror":"https://ror.org/01m6as704","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210106090"]},{"id":"https://openalex.org/I97188460","display_name":"Nantes Universit\u00e9","ror":"https://ror.org/03gnr7b55","country_code":"FR","type":"education","lineage":["https://openalex.org/I97188460"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Helene Senellart","raw_affiliation_strings":["Institut de Canc\u00e9rologie de l\u2019Ouest, Nantes, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut de Canc\u00e9rologie de l\u2019Ouest, Nantes, France","institution_ids":["https://openalex.org/I4210106090","https://openalex.org/I97188460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032656942","display_name":"C\u00e9cile de Labareyre","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cecile de Labareyre","raw_affiliation_strings":["GlaxoSmithKline Research and Development, Marly Le Roi, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline Research and Development, Marly Le Roi, France","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107936763","display_name":"Rodrigo Ruiz-Soto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4405268060","display_name":"GlaxoSmithKline Research & Development Limited (United Kingdom)","ror":"https://ror.org/05mayyh83","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405268060"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Rodrigo Ruiz-Soto","raw_affiliation_strings":["GlaxoSmithKline Research and Development, Stockley Park, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline Research and Development, Stockley Park, UK","institution_ids":["https://openalex.org/I188950975","https://openalex.org/I4405268060"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005304272","display_name":"Claire Wixon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4405268060","display_name":"GlaxoSmithKline Research & Development Limited (United Kingdom)","ror":"https://ror.org/05mayyh83","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405268060"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Claire Wixon","raw_affiliation_strings":["GlaxoSmithKline Research and Development, Stockley Park, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline Research and Development, Stockley Park, UK","institution_ids":["https://openalex.org/I188950975","https://openalex.org/I4405268060"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108524207","display_name":"Jeff Botbyl","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeff Botbyl","raw_affiliation_strings":["GlaxoSmithKline Research and Development, Upper Providence, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline Research and Development, Upper Providence, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046110397","display_name":"A. Benjamin Suttle","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Benjamin Suttle","raw_affiliation_strings":["GlaxoSmithKline Research and Development, Upper Providence, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline Research and Development, Upper Providence, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5028020706","display_name":"Jean\u2010Pierre Delord","orcid":"https://orcid.org/0000-0001-7305-5561","observed_orcids":["https://orcid.org/0000-0001-7305-5561"]},"institutions":[{"id":"https://openalex.org/I4210098740","display_name":"Institut universitaire du cancer de Toulouse Oncopole","ror":"https://ror.org/014hxhm89","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3019448017","https://openalex.org/I4210098740","https://openalex.org/I4210128666"]},{"id":"https://openalex.org/I4210128666","display_name":"Institut Claudius Regaud","ror":"https://ror.org/03pa87f90","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210128666"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Jean-Pierre Delord","raw_affiliation_strings":["Institut Claudius Regaud, D\u00e9partement de M\u00e9decine, IUCT-Oncopole, 1 Avenue Irene Joliot-Curie, CEDEX 9, 31059, Toulouse, France","Medical Oncology Department, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Claudius Regaud, D\u00e9partement de M\u00e9decine, IUCT-Oncopole, 1 Avenue Irene Joliot-Curie, CEDEX 9, 31059, Toulouse, France","institution_ids":["https://openalex.org/I4210128666"]},{"raw_affiliation_string":"Medical Oncology Department, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France","institution_ids":["https://openalex.org/I4210098740","https://openalex.org/I4210128666"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5028020706"],"corresponding_institution_ids":["https://openalex.org/I4210098740","https://openalex.org/I4210128666"],"apc_list":{"value":4690,"currency":"USD","value_usd":4690},"apc_paid":null,"fwci":0.8191,"has_fulltext":false,"cited_by_count":26,"citation_normalized_percentile":{"value":0.72180632,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"33","issue":"1","first_page":"138","last_page":"147"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pazopanib","display_name":"pazopanib","score":1.0},{"id":"https://openalex.org/keywords/irinotecan","display_name":"irinotecan","score":1.0},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":1.0},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.9940000176429749},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.8289999961853027},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.5490000247955322},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.824999988079071},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9079999923706055},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.9819999933242798},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.6269999742507935},{"id":"https://openalex.org/keywords/vegf-inhibitors","display_name":"VEGF inhibitors","score":0.5189999938011169}],"concepts":[{"id":"https://openalex.org/C2778439243","wikidata":"https://www.wikidata.org/wiki/Q7157043","display_name":"Pazopanib","level":4,"score":0.8986232280731201},{"id":"https://openalex.org/C2780259306","wikidata":"https://www.wikidata.org/wiki/Q412197","display_name":"Irinotecan","level":4,"score":0.8901762962341309},{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.8446340560913086},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7905917167663574},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7010806798934937},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6130254864692688},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.565505862236023},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5350948572158813},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5042656660079956},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.477340966463089},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.4357045590877533},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4249141216278076},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.31994128227233887},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3099547028541565},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.29944100975990295},{"id":"https://openalex.org/C2779490328","wikidata":"https://www.wikidata.org/wiki/Q417542","display_name":"Sunitinib","level":3,"score":0.08829307556152344}],"mesh":[{"descriptor_ui":"D000068818","descriptor_name":"Cetuximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077146","descriptor_name":"Irinotecan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007191","descriptor_name":"Indazoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009503","descriptor_name":"Neutropenia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D059004","descriptor_name":"Topoisomerase I Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D059004","descriptor_name":"Topoisomerase I Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D059004","descriptor_name":"Topoisomerase I Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1007/s10637-014-0142-1","doi":"https://doi.org/10.1007/s10637-014-0142-1","is_oa":false,"landing_page_url":"https://doi.org/10.1007/s10637-014-0142-1","pdf_url":null,"source":{"id":"https://openalex.org/S6037287","display_name":"Investigational New Drugs","issn_l":"0167-6997","issn":["0167-6997","1573-0646"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Investigational New Drugs","raw_type":"journal-article"},{"id":"pmid:25248752","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25248752","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Investigational new drugs","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[{"id":"https://openalex.org/G1872147869","display_name":"Cancer et Pharmacologie : Projet de Toulouse-Oncopole et de sa R\u00e9gion","funder_award_id":"ANR-11-PHUC-0001","funder_id":"https://openalex.org/F4320320883","funder_display_name":"Agence Nationale de la Recherche"}],"funders":[{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"},{"id":"https://openalex.org/F4320320883","display_name":"Agence Nationale de la Recherche","ror":"https://ror.org/00rbzpz17"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":30,"referenced_works":["https://openalex.org/W1568622226","https://openalex.org/W1847661643","https://openalex.org/W1994855668","https://openalex.org/W2006202974","https://openalex.org/W2078746475","https://openalex.org/W2087641304","https://openalex.org/W2095771928","https://openalex.org/W2096122707","https://openalex.org/W2097644228","https://openalex.org/W2098223440","https://openalex.org/W2111879300","https://openalex.org/W2116570461","https://openalex.org/W2121368761","https://openalex.org/W2125447919","https://openalex.org/W2128403792","https://openalex.org/W2128423996","https://openalex.org/W2128447158","https://openalex.org/W2134142320","https://openalex.org/W2139168548","https://openalex.org/W2139248078","https://openalex.org/W2142564546","https://openalex.org/W2143743735","https://openalex.org/W2150971555","https://openalex.org/W2157769714","https://openalex.org/W2162424705","https://openalex.org/W2164323018","https://openalex.org/W2167539263","https://openalex.org/W2168635453","https://openalex.org/W2227477053","https://openalex.org/W2804842145"],"related_works":["https://openalex.org/W2509069149","https://openalex.org/W1780046184","https://openalex.org/W2148829218","https://openalex.org/W2168635453","https://openalex.org/W2063857096","https://openalex.org/W1965450955","https://openalex.org/W7099836647","https://openalex.org/W2601786697","https://openalex.org/W1645010355","https://openalex.org/W1980177367"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":1}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2016-06-24T00:00:00"}